🙏Thank you very much for the great collaboration: Arndt Vogel Anna Saborowski David James Pinato 🇺🇦 Antonio D'Alessio Lorenza Rimassa Jeroen Dekervel Markus Peck Johann von Felden Lorenz Balcar Claudia Angela M. Fulgenzi and many more Editorial by: Marco Sanduzzi Zamparelli Giuseppe Cabibbo

Wonderful news - Conquer Cancer, the ASCO Foundation has chosen our work on neoadj ICI in HCC for the 2025 ASCO GI Merit Award🏅Pathological or radiological response as best RFS predictor? See you at my poster next Friday in San Francisco ! David James Pinato 🇺🇦 Surgery and Cancer ASCO conquer.org/news/conquer-c…

Ready for an exciting liver cancer day today at ASCO #GI25 ! Come to say hi at my poster E9 📃 and discover how pathological response to neoadj IO in HCC predicts RFS better than RECIST 🩻 Conquer Cancer, the ASCO Foundation David James Pinato 🇺🇦 Surgery and Cancer

CARES-005 is positive ! Another IO-TACE positive trial...but doubts remain 🧐 ❓PFS with TACE: 3.2 months only ❌ OS negative 🥈 phase 2 ASCO #GI25

RACB Study: interesting trial design of conversion therapy with AtezoBev in initially unresectable HCC 🩺 However: ❓ PR 13%, but resection rate 48% 🧐 Any grade AEs 66% ❌ No standardised definition of unresectable HCC ASCO #GI25

Do you remember adjuvant cell therapy for HCC? 🧫 At ASCO #GI25 the NINE year (!) f-up was presented: 📈 maintained significant RFS benefit 📍 reduction in cancer-specific death 🧪increase in CD8+ memory T cells Adjuvant therapy for HCC: not everything is lost ?

We'll done Angelo Pirozzi ! Super well deserved - can't wait to see your follow-up work ! x.com/angelopirozzi3…

Thank you Alessio Cortellini for the kind words and for chairing such an inspiring session - and thank you David James Pinato 🇺🇦 for organising it and making it possible !

Join us tomorrow onsite at #EASLCongress 2025! 🧪 EASL Molecular Tumour Board 📅 Wednesday 7 May, 13:30 - 14:30 CEST 📍 Hall 12 - Track Hub 3: Liver tumours 🔗 events-apps.easl.eu/easl2025/en-GB… Take part in this educational session to learn more about the challenges in diagnosis and

Are you at #easl2025 ? Don't miss this interactive session today ! See you at the Track Hub 3 - Liver Tumours at 13h30 EASL Education

Thank you EASL Education for the great session - today we learnt a lot about combined HCC-CCA 🎯 1. The diagnostic challenges - from the POV of pathology and radiology 2. How to integrate surgery and SIRT 3. Molecular profiling for targeted treatment Jean-Charles Nault Paradis valerie #easl2025

The calm before the storm... 🎙️ What a pleasure to share the stage with a stellar panel to talk about the challenges of ICI in HCC patients with impaired liver function at #easl25 EASL Education EASLnews

Great talk and discussion by Grainne O'Kane on #immunotherapy before #livertransplant for #HCC at #EASL2025 Sherrie Bhoori Antonio D'Alessio EASLnews EASL Education

Looking forward to seeing many friends and colleagues in Hong Kong !! ILCA

Explore the science driving change in liver cancer. At #ILCA25, join the session on Molecular Pathogenesis, Cell Biology & Translational Research, 19–21 Nov in Hong Kong. ilcalive.org/annual-confere… Carmen Wong CCLW Lab Amit G Singal maria reig Antonio D'Alessio Allaire Manon Stephen L. Chan

Quality of life matters in #HCC! Read our last network meta-analysis now online on JAMA Oncology David James Pinato 🇺🇦 Giuseppe Cabibbo Antonio D'Alessio Claudia Angela M. Fulgenzi Bernardo Stefanini Giulia Francesca Manfredi Pasquale Lombardi jamanetwork.com/journals/jamao…

ESMO-HCC🗞️ What can we learn from negative studies? Brilliant discussion from Lorenza Rimassa -Nofazinlimab (PD1i)+lenvatinib did not improve OS vs lenva: comparable results with LEAP002, no unexpected safety signals -TRIPLET-HCC (IPI+AteBev): more is not always better #ESMO25

ESMO-HCC 🗞️ Great overview by David James Pinato 🇺🇦 on how to combine systemic therapy with locoregional treatments in HCC 💊 #ESMO25 Surgery and Cancer

Is this the death 🪦 of anti-TIGIT? Disappointing negative results for the IMbrave152/SKYSCRAPER-14 phase 3 study at #ESMO25

First positive Phase 3 trial in the perioperative setting for HCC #ESMO25 ! ✂️💊 The concomitant Lancet publication says it all 🗞️ However: -15% BCLC C -Adj TACE? -Why the MPR 50%? -Only a minority completes the adjuvant -Crossover to camre/rivo also for intrahepatic relapse?